Srinivasan Ayyanaar1, Chandrasekar Balachandran2, Rangaswamy Chinnabba Bhaskar3, Mookkandi Palsamy Kesavan4, Shin Aoki2,5, Ramachandran Palpandi Raja6, Jegathalaprathaban Rajesh7, Thomas J Webster8, Gurusamy Rajagopal1. 1. PG and Research Department of Chemistry, Chikkanna Government Arts College, Tiruppur 641 602, Tamilnadu, India. 2. Faculty of Pharmaceutical Sciences, Tokyo University of Science, Noda 278-8510, Japan. 3. Department of Chemistry, School of Advanced Sciences, Vellore Institute of Technology, Vellore 632014, Tamil Nadu, India. 4. Department of Chemistry, Hajee Karutha Rowther Howdia College, Uthamapalayam 625 533, Tamil Nadu, India. 5. Research Institute of Science and Technology, Tokyo University of Science, Noda 278-8510, Japan. 6. Centre for Biotechnology, Anna University, Chennai 600 025, Tamil Nadu, India. 7. Chemistry Research Centre, Mohamed Sathak Engineering College, Kilakarai 623 806, Tamil Nadu, India. 8. Department of Chemical Engineering, Northeastern University, Boston, MA 02115, USA.
Abstract
BACKGROUND AND OBJECTIVE: Cancer cells accumulate high concentrations of reactive oxygen species as a result of their faster and uninhibited metabolic activity. Cancer chemotherapeutic agents release an excess of severe adverse reactions as a result of targeting normal cells. This demands an improvement in targeted drug-delivery systems to selectively discharge anticancer drugs in the vicinity of such highly metabolically and mitotically active cells. MATERIALS AND METHODS: Here, magnetic nanoparticles were synthesized by a traditional co-precipitation technique. Fe3O4@OA-CS-5-FLU-NPs were synthesized by an easy and rapid in situ loading method. The proposed Fe3O4@OA-CS-5-FLU-NPs were productively prepared as well as characterized by various spectroscopic and microscopic studies. RESULTS: The targeted drug release profile of the Fe3O4@OA-CS-5-FLU-NPs was studied in the presence of ROS including H2O2 and pH induction. The released product, Fe3O4@OA-CS-5-FLU-NP, exhibited desirable levels of cytotoxicity and demonstrated morphological changes and inhibition of colony formation for A549 and HeLa S3 cancer cells. The IC50 values at 24 hours were 12.9 and 23 μg/mL, respectively. CONCLUSION: In summary, results from the MTT assay, fluorescence staining as well as colony formation assays, revealed that the Fe3O4@OA-CS-5-FLU-NPs were active and safe for anticancer biomedical applications. In summary, the present investigation provides a powerful nanostructured based system for improved cancer theranostics that should be further studied.
BACKGROUND AND OBJECTIVE: Cancer cells accumulate high concentrations of reactive oxygen species as a result of their faster and uninhibited metabolic activity. Cancer chemotherapeutic agents release an excess of severe adverse reactions as a result of targeting normal cells. This demands an improvement in targeted drug-delivery systems to selectively discharge anticancer drugs in the vicinity of such highly metabolically and mitotically active cells. MATERIALS AND METHODS: Here, magnetic nanoparticles were synthesized by a traditional co-precipitation technique. Fe3O4@OA-CS-5-FLU-NPs were synthesized by an easy and rapid in situ loading method. The proposed Fe3O4@OA-CS-5-FLU-NPs were productively prepared as well as characterized by various spectroscopic and microscopic studies. RESULTS: The targeted drug release profile of the Fe3O4@OA-CS-5-FLU-NPs was studied in the presence of ROS including H2O2 and pH induction. The released product, Fe3O4@OA-CS-5-FLU-NP, exhibited desirable levels of cytotoxicity and demonstrated morphological changes and inhibition of colony formation for A549 and HeLa S3 cancer cells. The IC50 values at 24 hours were 12.9 and 23 μg/mL, respectively. CONCLUSION: In summary, results from the MTT assay, fluorescence staining as well as colony formation assays, revealed that the Fe3O4@OA-CS-5-FLU-NPs were active and safe for anticancer biomedical applications. In summary, the present investigation provides a powerful nanostructured based system for improved cancer theranostics that should be further studied.
Authors: Xianqiao Liu; Michael D Kaminski; Haitao Chen; Michael Torno; LaToyia Taylor; Axel J Rosengart Journal: J Control Release Date: 2007-02-02 Impact factor: 9.776
Authors: José L Arias; M A Adolfina Ruiz; Margarita López-Viota; Angel V Delgado Journal: Colloids Surf B Biointerfaces Date: 2007-09-21 Impact factor: 5.268